EA202090005A1 - Антитела, модулирующие биологическую активность, проявляемую клеткой - Google Patents

Антитела, модулирующие биологическую активность, проявляемую клеткой

Info

Publication number
EA202090005A1
EA202090005A1 EA202090005A EA202090005A EA202090005A1 EA 202090005 A1 EA202090005 A1 EA 202090005A1 EA 202090005 A EA202090005 A EA 202090005A EA 202090005 A EA202090005 A EA 202090005A EA 202090005 A1 EA202090005 A1 EA 202090005A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lag
cell
bind
variable domain
biological activity
Prior art date
Application number
EA202090005A
Other languages
English (en)
Inventor
Сесилия Анна Вильгельмина Гёин
Ринсе Клостер
Корнелис Адриан Де Крёйф
Паулус Йоханнес Таккен
Марк Тросби
Тон Логтенберг
Original Assignee
Мерус Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерус Н.В. filed Critical Мерус Н.В.
Publication of EA202090005A1 publication Critical patent/EA202090005A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение обеспечивает средства и способы препятствования опосредуемому белком запрограммированной гибели клеток 1 (Programmed Cell Death 1 белок (PD-1)) и активатором лимфоцитов 3 (LAG-3), ингибированию в PD-1-положительной и/или LAG-3-положительной клетке. Способ может включать приведение указанной клетки в контакт с антителом или его функциональной частью, производным и/или аналогом, содержащими вариабельный домен, который может связываться с внеклеточной частью PD-1, и вариабельный домен, который может связываться с внеклеточной частью LAG-3, тем самым ингибируя опосредуемую PD-1 и/или LAG-3 активность в указанной клетке. Изобретение также обеспечивает антитела или их варианты, содержащие вариабельный домен, который может связываться с внеклеточной частью PD-1, и вариабельный домен, который может связываться с внеклеточной частью LAG-3.
EA202090005A 2017-07-06 2018-07-06 Антитела, модулирующие биологическую активность, проявляемую клеткой EA202090005A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17180070 2017-07-06
PCT/NL2018/050451 WO2019009728A1 (en) 2017-07-06 2018-07-06 ANTIBODIES THAT MODULATE A BIOLOGICAL ACTIVITY EXPRESSED BY A CELL

Publications (1)

Publication Number Publication Date
EA202090005A1 true EA202090005A1 (ru) 2020-06-18

Family

ID=59295099

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090005A EA202090005A1 (ru) 2017-07-06 2018-07-06 Антитела, модулирующие биологическую активность, проявляемую клеткой

Country Status (15)

Country Link
US (2) US11732043B2 (ru)
EP (1) EP3649156A1 (ru)
JP (2) JP7542436B2 (ru)
KR (1) KR20200037250A (ru)
CN (3) CN118027197A (ru)
AU (1) AU2018297061B2 (ru)
BR (1) BR112020000228A2 (ru)
CA (1) CA3068933A1 (ru)
EA (1) EA202090005A1 (ru)
IL (1) IL271833B2 (ru)
NZ (1) NZ760655A (ru)
PH (1) PH12020550010A1 (ru)
SG (1) SG11202000055PA (ru)
TW (1) TW201920275A (ru)
WO (1) WO2019009728A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3037380A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
JP7183163B2 (ja) 2017-01-06 2022-12-05 クレシェンド・バイオロジックス・リミテッド プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体
KR20200083574A (ko) 2017-11-13 2020-07-08 크레센도 바이오로직스 리미티드 Cd137 및 psma에 결합하는 분자
GB201802573D0 (en) * 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
CN112236456B (zh) * 2018-03-20 2023-12-22 上海药明生物技术有限公司 新型双特异性pd-1/lag-3抗体分子
JP2021519610A (ja) * 2018-03-30 2021-08-12 メルス ナムローゼ フェンノートシャップ 多価抗体
US20220213192A1 (en) * 2019-04-26 2022-07-07 WuXi Biologics Ireland Limited Bispecific antibodies against pd-1 and lag-3
MA55884A (fr) 2019-05-09 2022-03-16 Merus Nv Domaines variants pour la multimérisation de protéines et leur séparation
AU2021278998A1 (en) * 2020-05-27 2022-11-03 Agilent Technologies, Inc. Anti-human LAG-3 antibodies and their use in immunohistochemistry (IHC)
CN112225813B (zh) * 2020-10-21 2021-12-21 北京智仁美博生物科技有限公司 针对破伤风毒素的抗体及其用途
EP4019633A1 (en) * 2020-12-23 2022-06-29 Technische Universität München Conditional cell connectors
US20240309115A1 (en) 2021-03-31 2024-09-19 Merus N.V. Novel multispecific antibodies
CN117177994A (zh) * 2021-03-31 2023-12-05 美勒斯公司 包含新颖pd-1结合域之多特异性结合部分
IL307316A (en) 2021-03-31 2023-11-01 Merus Nv New binding regions for PD-1
TW202421193A (zh) * 2022-09-28 2024-06-01 美商英塞特公司 抗ｐｄ－１／ｌａｇ－３雙特異性抗體及其用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
CN117534755A (zh) 2005-05-09 2024-02-09 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
EP2860260A1 (en) 2008-04-11 2015-04-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
PT2147594E (pt) 2008-06-27 2014-02-17 Merus B V Mamíferos não humanos que produzem anticorpos
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US8927697B2 (en) 2008-09-12 2015-01-06 Isis Innovation Limited PD-1 specific antibodies and uses thereof
JP5794917B2 (ja) 2008-09-12 2015-10-14 アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ Ｐｄ−１特異抗体およびその使用
EP2699264B1 (en) 2011-04-20 2018-03-14 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
EP3939613A1 (en) 2011-08-11 2022-01-19 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
EA035344B1 (ru) 2012-04-20 2020-05-29 Мерюс Н.В. Способ получения двух антител из одной клетки-хозяина
BR112015006824A2 (pt) 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
SI3116909T1 (sl) * 2014-03-14 2020-03-31 Novartis Ag Molekule protiteles na LAG-3 in njih uporaba
TWI693232B (zh) * 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
WO2016011069A1 (en) 2014-07-15 2016-01-21 The Board Of Trustees Of The Leland Stanford Junior University Medical uses of cd38 agonists (antibodies)
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016210129A1 (en) * 2015-06-23 2016-12-29 Memorial Sloan-Kettering Cancer Center Novel pd-1 immune modulating agents
SG10201906059VA (en) * 2015-07-30 2019-08-27 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
WO2017024515A1 (en) * 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
US11124569B2 (en) 2015-09-18 2021-09-21 Dana-Farber Cancer Institute, Inc. Methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptors
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
PL3365373T3 (pl) 2015-10-23 2021-08-23 Merus N.V. Molekuły wiążące, które hamują wzrost nowotworu
KR102220275B1 (ko) * 2015-11-18 2021-02-26 머크 샤프 앤드 돔 코포레이션 Pd1 및/또는 lag3 결합제
EA201990747A1 (ru) 2016-09-19 2019-10-31 Способы лечения иммунных нарушений с применением белков, связывающих pd–1
JP2019534859A (ja) 2016-09-19 2019-12-05 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
EA201990578A1 (ru) * 2016-09-23 2019-10-31 Связывающие молекулы, которые модулируют биологическую активность, проявляемую клеткой
KR102236259B1 (ko) 2017-02-22 2021-04-06 아이-맵 바이오파마 유에스 리미티드 항-lag-3 항체 및 그것의 사용
EP3589600B1 (de) 2017-03-01 2021-11-17 Fluorchemie GmbH Frankfurt Neuartiges material, sowie dessen herstellung zur anwendung als speichermedium im sensitiven energiespeichersystem im niederen, mittleren und hochtemperaturbereich
DE202017102208U1 (de) 2017-03-03 2018-03-07 Sarah Yanik Zusammensetzung, insbesondere für die Behandlung von Huf- und Klauenerkrankungen bei Tieren, und deren Herstellung
WO2019009727A1 (en) * 2017-07-06 2019-01-10 Merus N.V. ANTI-PD1 ANTI-TIM3 BISPECIFIC ANTIBODIES
SG11202000014UA (en) * 2017-07-06 2020-01-30 Merus Nv Binding molecules that modulate a biological activity expressed by a cell
JP7375027B2 (ja) * 2019-02-14 2023-11-07 メルス ナムローゼ フェンノートシャップ ２つ以上の抗体を含む組成物の製造
KR20230029611A (ko) 2020-05-27 2023-03-03 다나-파버 캔서 인스티튜트 인크. T 세포를 선택적으로 조절하기 위한 이중특이적 분자

Also Published As

Publication number Publication date
US20200216540A1 (en) 2020-07-09
JP2020525533A (ja) 2020-08-27
JP7542436B2 (ja) 2024-08-30
CN111094350A (zh) 2020-05-01
AU2018297061A1 (en) 2020-01-30
CN111094350B (zh) 2024-09-03
JP2024086853A (ja) 2024-06-28
WO2019009728A1 (en) 2019-01-10
TW201920275A (zh) 2019-06-01
CN117964759A (zh) 2024-05-03
KR20200037250A (ko) 2020-04-08
IL271833B1 (en) 2024-05-01
AU2018297061B2 (en) 2021-05-06
SG11202000055PA (en) 2020-02-27
EP3649156A1 (en) 2020-05-13
PH12020550010A1 (en) 2020-10-12
BR112020000228A2 (pt) 2020-07-14
CA3068933A1 (en) 2019-01-10
US11732043B2 (en) 2023-08-22
NZ760655A (en) 2024-07-05
IL271833B2 (en) 2024-09-01
IL271833A (en) 2020-02-27
CN118027197A (zh) 2024-05-14
WO2019009728A8 (en) 2020-01-09
US20230406932A1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
EA202090005A1 (ru) Антитела, модулирующие биологическую активность, проявляемую клеткой
EA202090004A1 (ru) Биспецифические антитела против pd-1 и против tim-3
CY1124232T1 (el) Συνδετικα μορια συνδεσης pd-l1 και lag-3
MX2022006447A (es) Anticuerpos anti-pd-1 novedosos.
SA518390862B1 (ar) Pd-l1 أجسام مضادة ضد
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
BR112018010410A2 (pt) método para tratar câncer em um sujeito, composição e métodos de aumento do número de células nk e de aumento do número de uma ou mais células positivas para pd-l1
EA201990747A1 (ru) Способы лечения иммунных нарушений с применением белков, связывающих pd–1
EA201890790A1 (ru) Связывающие pd-1 белки и способы их применения
MY201526A (en) Anti-trem2 antibodies and methods of use thereof
EA201591467A1 (ru) Анти-lag-3 связывающие белки
PH12017502222A1 (en) Lag-3-binding molecules and methods of use thereof
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
CO2017007665A2 (es) Proteínas de unión a icos
EA201900561A1 (ru) Конъюгаты циклодекстрин-белок-лекарственное средство
EA201990530A1 (ru) Пути применения ингибиторов pd-1/pd-l1 и/или ингибиторов ctla-4 с биологическим средством, содержащим несколько цитокиновых компонентов, для лечения рака
MX2018001387A (es) Anticuerpo de dominio simple y proteinas derivadas del mismo contra ligando de muerte programada (pdl1).
EA201890278A1 (ru) Антитела к pd-l1
MY189159A (en) Multispecific antigen-binding molecules and uses thereof
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
EA201790439A1 (ru) Способы лечения множественной миеломы с применением иммуномодулирующих соединений в комбинации с антителами
EA202091888A1 (ru) Вариабельные домены антител, нацеленные на рецептор nkg2d
PH12021550332A1 (en) Anti-cd33 antibodies and methods of use thereof
EA202092088A1 (ru) Антитела анти-phf-тау и их применение